PL3277270T3 - Kompozycje i sposoby leczenia niedokrwistości - Google Patents
Kompozycje i sposoby leczenia niedokrwistościInfo
- Publication number
- PL3277270T3 PL3277270T3 PL16774184T PL16774184T PL3277270T3 PL 3277270 T3 PL3277270 T3 PL 3277270T3 PL 16774184 T PL16774184 T PL 16774184T PL 16774184 T PL16774184 T PL 16774184T PL 3277270 T3 PL3277270 T3 PL 3277270T3
- Authority
- PL
- Poland
- Prior art keywords
- isknia
- compositions
- treatment
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562141420P | 2015-04-01 | 2015-04-01 | |
| US201562270168P | 2015-12-21 | 2015-12-21 | |
| PCT/US2016/025235 WO2016161094A1 (en) | 2015-04-01 | 2016-03-31 | Compositions and methods for treating anemia |
| EP16774184.2A EP3277270B1 (en) | 2015-04-01 | 2016-03-31 | Compositions and methods for treating anemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3277270T3 true PL3277270T3 (pl) | 2022-02-14 |
Family
ID=57006457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16774184T PL3277270T3 (pl) | 2015-04-01 | 2016-03-31 | Kompozycje i sposoby leczenia niedokrwistości |
Country Status (35)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009000286A (es) | 2006-06-26 | 2009-03-20 | Procter & Gamble | Inhibidores de prolil hidroxilasa y metodos de uso. |
| NO2686520T3 (cg-RX-API-DMAC7.html) | 2011-06-06 | 2018-03-17 | ||
| PT3007695T (pt) | 2013-06-13 | 2024-03-07 | Akebia Therapeutics Inc | Composições e métodos para tratamento de anemia |
| AR099354A1 (es) | 2013-11-15 | 2016-07-20 | Akebia Therapeutics Inc | Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos |
| CN107427503A (zh) | 2015-01-23 | 2017-12-01 | 阿克比治疗有限公司 | 2‑(5‑(3‑氟苯基)‑3‑羟基吡啶甲酰胺)乙酸的固体形式、其组合物及用途 |
| CR20170450A (es) | 2015-04-01 | 2018-04-03 | Akebia Therapeutics Inc | Composiciones y métodos para el tratamiento de la anemia |
| JP6864834B2 (ja) | 2017-06-14 | 2021-04-28 | ニプロ株式会社 | 投与量決定プログラムおよび投与量決定装置 |
| WO2019028150A1 (en) | 2017-08-01 | 2019-02-07 | Akebia Therapeutics, Inc. | COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES |
| US11713298B2 (en) | 2018-05-09 | 2023-08-01 | Akebia Therapeutics, Inc. | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
| JP2023501221A (ja) * | 2019-10-31 | 2023-01-18 | アケビア セラピューティクス インコーポレイテッド | バダデュスタットを使用する治療方法 |
| US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
| WO2021186356A1 (en) * | 2020-03-17 | 2021-09-23 | Cadila Healthcare Limited | Formulation comprising hif prolyl hydroxylase inhibitors |
| US20210353612A1 (en) * | 2020-04-29 | 2021-11-18 | BioAge Labs, Inc. | Hypoxia-inducible factor prolyl hydroxylase inhibitors for treating aging-related conditions |
| CA3180509A1 (en) * | 2020-06-19 | 2021-12-23 | Sayantan CHATTORAJ | Formulation comprising daprodustat |
| EP4181873A1 (en) | 2020-06-19 | 2023-05-24 | Akebia Therapeutics Inc. | Modulation of drug-drug interactions of vadadustat |
| US20220034871A1 (en) * | 2020-07-31 | 2022-02-03 | Daiichi Sankyo Company, Limited | Methods for administering pexidartinib |
| WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
| AU2022206302A1 (en) | 2021-01-08 | 2023-08-17 | Akebia Therapeutics, Inc. | Therapeutic methods using vadadustat |
| JP2024510926A (ja) | 2021-03-01 | 2024-03-12 | アケビア セラピューティクス インコーポレイテッド | バダデュスタットの薬物間相互作用の調節 |
| CN119868550A (zh) * | 2023-10-24 | 2025-04-25 | 杭州安道药业有限公司 | 缺氧诱导因子-脯酰胺羟基化酶抑制剂（hif-phi）在罕见贫血中的应用 |
Family Cites Families (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3655679A (en) | 1969-06-25 | 1972-04-11 | Merck & Co Inc | Certain aryl pyridine carboxylic acid derivatives |
| US3703582A (en) | 1970-04-20 | 1972-11-21 | Merck & Co Inc | Aryl pyridine carboxylic acids in the treatment of inflammation |
| US3894920A (en) | 1971-12-21 | 1975-07-15 | Sagami Chem Res | Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives |
| US4016287A (en) | 1972-07-17 | 1977-04-05 | Boehringer Ingelheim Gmbh | Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof |
| CA1261335A (en) | 1984-08-29 | 1989-09-26 | Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee | Ethylenediamine monoamide derivatives |
| CN1023479C (zh) | 1985-09-27 | 1994-01-12 | 弗·哈夫曼-拉罗切有限公司 | 乙二胺的单酰胺衍生物的制备方法 |
| TW219933B (cg-RX-API-DMAC7.html) | 1990-02-26 | 1994-02-01 | Lilly Co Eli | |
| US5405613A (en) | 1991-12-11 | 1995-04-11 | Creative Nutrition Canada Corp. | Vitamin/mineral composition |
| TW352384B (en) | 1992-03-24 | 1999-02-11 | Hoechst Ag | Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals |
| DE4219158A1 (de) | 1992-06-11 | 1993-12-16 | Thomae Gmbh Dr K | Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DE59401923D1 (de) | 1993-11-02 | 1997-04-10 | Hoechst Ag | Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
| EP0650961B1 (de) | 1993-11-02 | 1997-03-05 | Hoechst Aktiengesellschaft | Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| TW406076B (en) | 1993-12-30 | 2000-09-21 | Hoechst Ag | Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals |
| DE4410423A1 (de) | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE4410480A1 (de) | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US5789426A (en) | 1995-01-20 | 1998-08-04 | Cornell Research Foundation, Inc. | Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation |
| IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
| JPH09221476A (ja) | 1995-12-15 | 1997-08-26 | Otsuka Pharmaceut Co Ltd | 医薬組成物 |
| WO1997041103A1 (de) | 1996-04-30 | 1997-11-06 | Hoechst Aktiengesellschaft | 3-alkoxypyridin-2-carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel |
| DE19620041A1 (de) | 1996-05-17 | 1998-01-29 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| DE19650215A1 (de) | 1996-12-04 | 1998-06-10 | Hoechst Ag | 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
| EP1024134A4 (en) | 1997-10-09 | 2003-05-14 | Ono Pharmaceutical Co | DERIVATIVES OF AMINOBUTANIC ACID |
| DE19746287A1 (de) | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| JP4495339B2 (ja) | 1998-03-23 | 2010-07-07 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | ピペリジニルおよびｎ−アミジノピペリジニル誘導体 |
| US6159379A (en) | 1999-05-04 | 2000-12-12 | Baker Hughes Incorporated | Organic ammonium salts for the removal of water soluble organics in produced water |
| JP2001048786A (ja) | 1999-08-05 | 2001-02-20 | Yamanouchi Pharmaceut Co Ltd | 三環式ヘテロアリール誘導体 |
| DK1265608T3 (da) | 2000-03-22 | 2008-12-08 | Pharmacia & Upjohn Co Llc | Oxazolidinon tabletformulering |
| US6589758B1 (en) | 2000-05-19 | 2003-07-08 | Amgen Inc. | Crystal of a kinase-ligand complex and methods of use |
| US6849718B2 (en) | 2001-03-20 | 2005-02-01 | Dana Farber Cancer Institute, Inc. | Muteins of hypoxia inducible factor alpha and methods of use thereof |
| US6855510B2 (en) | 2001-03-20 | 2005-02-15 | Dana Farber Cancer Institute, Inc. | Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| JP4590157B2 (ja) | 2001-03-21 | 2010-12-01 | アイシス イノヴェイション リミテッド | アッセイ、方法および手段 |
| SE0101327D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | New crystalline forms |
| US6566088B1 (en) | 2001-10-04 | 2003-05-20 | Board Of Regents, The University Of Texas System | Prolyl-4-hydroxylases |
| GB0124941D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| ES2686625T3 (es) | 2001-12-06 | 2018-10-18 | Fibrogen, Inc. | Métodos para el tratamiento o prevención de la anemia |
| WO2003097040A1 (en) | 2002-05-17 | 2003-11-27 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| AU2003265674B2 (en) | 2002-08-29 | 2008-12-11 | Merck & Co., Inc. | N-biarylmethyl aminocycloalkanecarboxamide derivatives |
| EP1554394B1 (en) | 2002-10-16 | 2009-12-16 | Isis Innovation Limited | Screening methods using a structural model of FIH |
| CA2506799A1 (en) | 2002-11-21 | 2004-06-10 | Eli Lilly And Company | Mixed lineage kinase modulators |
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
| US7183287B2 (en) | 2003-04-03 | 2007-02-27 | Pharmacia Corporation | Substituted pyrimidinones |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| KR100932169B1 (ko) | 2003-06-06 | 2009-12-16 | 피브로겐, 인크. | 질소-함유 헤테로아릴 화합물 및 내인성 적혈구생성소의증가에서의 그들의 사용 |
| US20060251638A1 (en) | 2003-06-06 | 2006-11-09 | Volkmar Guenzler-Pukall | Cytoprotection through the use of hif hydroxylase inhibitors |
| GB0314129D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| JPWO2005108370A1 (ja) | 2004-04-16 | 2008-03-21 | 味の素株式会社 | ベンゼン化合物 |
| ES2332798T3 (es) | 2004-05-28 | 2010-02-12 | Fibrogen, Inc. | Ensayo de actividad de la prolil hidroxilasa de hif. |
| EP1771418A2 (en) | 2004-05-31 | 2007-04-11 | Tanabe Seiyaku Co., Ltd. | Large conductance calcium-activated k channel opener |
| CA2573185A1 (en) | 2004-07-14 | 2006-02-23 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
| TW200616969A (en) | 2004-09-17 | 2006-06-01 | Tanabe Seiyaku Co | Imidazole compound |
| DE05815688T1 (de) * | 2005-01-27 | 2008-06-26 | Alembic Ltd. | Levetiracetam-formulierung mit verlängerter freisetzung |
| US20080213404A1 (en) | 2005-02-04 | 2008-09-04 | Johnson Randall S | Hif Modulating Compounds and Methods of Use Thereof |
| DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| CN101849943A (zh) | 2005-06-06 | 2010-10-06 | 菲布罗根公司 | 使用HIFα稳定剂的改进的贫血治疗 |
| EP1919463B9 (en) | 2005-06-15 | 2011-02-02 | Fibrogen, Inc. | Use of hif 1alfa modulators for treatment of cancer |
| WO2007033216A2 (en) | 2005-09-12 | 2007-03-22 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
| WO2007038571A2 (en) | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
| US20090176726A1 (en) | 2005-10-11 | 2009-07-09 | Fisher David E | Methods for treating mitf-related disorders |
| US7728130B2 (en) | 2005-12-09 | 2010-06-01 | Amgen Inc. | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity |
| GB2453819A (en) | 2006-01-09 | 2009-04-22 | Btg Int Ltd | Modulators of hypoxia inducible factor-1 and related uses |
| WO2007082899A1 (en) | 2006-01-17 | 2007-07-26 | Vib Vzw | Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration |
| JP4801451B2 (ja) | 2006-01-19 | 2011-10-26 | 株式会社日立ハイテクノロジーズ | 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法 |
| TW200738709A (en) | 2006-01-19 | 2007-10-16 | Osi Pharm Inc | Fused heterobicyclic kinase inhibitors |
| ITMI20060179A1 (it) | 2006-02-02 | 2007-08-03 | Abiogen Pharma Spa | Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse |
| US7625927B2 (en) | 2006-02-27 | 2009-12-01 | Alcon Research, Ltd. | Method of treating glaucoma |
| US7588924B2 (en) | 2006-03-07 | 2009-09-15 | Procter & Gamble Company | Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase |
| AR059733A1 (es) | 2006-03-07 | 2008-04-23 | Smithkline Beecham Corp | Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion |
| ES2288117B1 (es) | 2006-05-08 | 2008-12-01 | Combino Pharm, S.L. | Composicion farmaceutica solida de gabapentina. |
| US20090176825A1 (en) | 2006-05-16 | 2009-07-09 | Fitch Duke M | Prolyl hydroxylase inhibitors |
| AR061570A1 (es) | 2006-06-23 | 2008-09-03 | Smithkline Beecham Corp | Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto |
| MX2009000286A (es) | 2006-06-26 | 2009-03-20 | Procter & Gamble | Inhibidores de prolil hidroxilasa y metodos de uso. |
| CL2008000066A1 (es) | 2007-01-12 | 2008-08-01 | Smithkline Beecham Corp | Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem |
| TW200845994A (en) | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: prolyl hydroxylase inhibitors |
| JP2008201711A (ja) * | 2007-02-20 | 2008-09-04 | Ss Pharmaceut Co Ltd | システイン臭が低減された固形製剤 |
| CN101663037A (zh) | 2007-04-18 | 2010-03-03 | 默克公司 | 新的1,8-二氮杂萘化合物 |
| ES2446418T3 (es) | 2007-04-18 | 2014-03-07 | Amgen, Inc | Derivados de indanona que inhiben la prolil hidroxilasa |
| ES2389063T3 (es) | 2007-05-04 | 2012-10-22 | Amgen, Inc | Derivados de tienopiridina y tiazolopiridina que inhiben la actividad prolil hidroxilasa |
| WO2008144266A1 (en) | 2007-05-16 | 2008-11-27 | Merck & Co., Inc. | Spiroindalones |
| RU2009146851A (ru) | 2007-05-18 | 2011-06-27 | Байер Шеринг Фарма Акциенгезельшафт (DE) | Гетероарил-замещенные пиразольные производные, которые могут использоваться для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом |
| EP2186528B1 (en) | 2007-08-06 | 2014-03-19 | Senju Pharmaceutical Co., Ltd. | Pharmaceutical containing hif-1 alpha and hif-2 alpha expression inhibitor |
| TW200908984A (en) | 2007-08-07 | 2009-03-01 | Piramal Life Sciences Ltd | Pyridyl derivatives, their preparation and use |
| CN101815718A (zh) | 2007-08-10 | 2010-08-25 | 克里斯捷诺米有限公司 | 吡啶衍生物及其用法 |
| WO2009035534A2 (en) | 2007-09-07 | 2009-03-19 | The Cleveland Clinic Foundation | Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif) |
| WO2009039321A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009039323A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009043093A1 (en) | 2007-10-04 | 2009-04-09 | Newsouth Innovations Pty Limited | Hif inhibition |
| WO2009049112A1 (en) | 2007-10-10 | 2009-04-16 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009067790A1 (en) | 2007-11-26 | 2009-06-04 | Uti Limited Partnership | STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION |
| AU2008331480A1 (en) | 2007-11-30 | 2009-06-11 | Glaxosmithkline Llc | Prolyl hydroxylase inhibitors |
| EA201000920A1 (ru) | 2007-11-30 | 2011-02-28 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Ингибиторы пролилгидроксилазы |
| US8269008B2 (en) | 2007-12-03 | 2012-09-18 | Fibrogen, Inc. | Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions |
| US20100298324A1 (en) | 2007-12-19 | 2010-11-25 | Smith Kline Beecham Corporation | Prolyl Hydroxylase Inhibitors |
| WO2009086592A1 (en) | 2008-01-04 | 2009-07-16 | Garvan Institute Of Medical Research | Method of increasing metabolism |
| US8952160B2 (en) | 2008-01-11 | 2015-02-10 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity |
| JP5380465B2 (ja) | 2008-03-03 | 2014-01-08 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Ｔｌｒ活性モジュレーターとしての化合物および組成物 |
| WO2010010017A1 (en) | 2008-07-23 | 2010-01-28 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| NZ591394A (en) | 2008-09-15 | 2013-03-28 | Kasina Laila Innova Pharmaceuticals Private Ltd | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers |
| AU2009314155B2 (en) | 2008-11-14 | 2015-10-08 | Fibrogen, Inc. | Thiochromene derivatives as HIF hydroxylase inhibitors |
| HRP20130846T1 (hr) | 2009-03-31 | 2013-11-22 | Kissei Pharmaceutical Co., Ltd. | Derivati indolizina i njihova uporaba u medicinske svrhe |
| PL2496236T4 (pl) | 2009-11-06 | 2015-11-30 | Aerpio Therapeutics Inc | Inhibitory hydroksylazy prolilowej |
| JO2978B1 (en) | 2009-12-21 | 2016-03-15 | ايلي ليلي اند كومباني | MGLU2 aids |
| CN103429239A (zh) | 2011-01-13 | 2013-12-04 | 菲布罗根有限公司 | 增加网织红细胞血红蛋白含量的方法 |
| CA2837560C (en) | 2011-06-06 | 2017-02-14 | Akebia Therapeutics Inc. | Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer |
| NO2686520T3 (cg-RX-API-DMAC7.html) | 2011-06-06 | 2018-03-17 | ||
| US20130022974A1 (en) | 2011-06-17 | 2013-01-24 | The Regents Of The University Of Michigan | Dna methylation profiles in cancer |
| US9206134B2 (en) | 2011-07-22 | 2015-12-08 | Beijing Betta Pharmaceuticals Co. Ltd. | Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof |
| US20140309256A1 (en) | 2011-11-09 | 2014-10-16 | Fibrogen, Inc. | Therapeutic Method |
| JP2015537013A (ja) | 2012-11-19 | 2015-12-24 | アサンタ・アー／エス | 速崩性錠剤 |
| JP2016519684A (ja) * | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物 |
| RS60464B1 (sr) * | 2013-06-06 | 2020-07-31 | Fibrogen Inc | Farmaceutske formulacije inhibitora hif hidroksilaze |
| PT3007695T (pt) * | 2013-06-13 | 2024-03-07 | Akebia Therapeutics Inc | Composições e métodos para tratamento de anemia |
| RU2016109125A (ru) | 2013-08-16 | 2017-09-22 | Огайо Стейт Инновейшн Фаундейшн | Композиции и способы модуляции метилирования днк |
| AR099354A1 (es) | 2013-11-15 | 2016-07-20 | Akebia Therapeutics Inc | Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos |
| WO2015112831A1 (en) | 2014-01-23 | 2015-07-30 | Akebia Therapeutics, Inc. | Compositions and methods for treating ocular diseases |
| US10617716B2 (en) | 2014-12-16 | 2020-04-14 | Urgo Us, Inc. | Hypochlorous acid formulations and methods for treating skin conditions |
| CN107427503A (zh) | 2015-01-23 | 2017-12-01 | 阿克比治疗有限公司 | 2‑(5‑(3‑氟苯基)‑3‑羟基吡啶甲酰胺)乙酸的固体形式、其组合物及用途 |
| WO2016153996A1 (en) | 2015-03-20 | 2016-09-29 | Akebia Therapeutics, Inc. | Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors |
| CR20170450A (es) | 2015-04-01 | 2018-04-03 | Akebia Therapeutics Inc | Composiciones y métodos para el tratamiento de la anemia |
-
2016
- 2016-03-31 CR CR20170450A patent/CR20170450A/es unknown
- 2016-03-31 MX MX2020009415A patent/MX386796B/es unknown
- 2016-03-31 CU CUP2017000126A patent/CU20170126A7/xx unknown
- 2016-03-31 PH PH1/2017/501789A patent/PH12017501789B1/en unknown
- 2016-03-31 KR KR1020177031649A patent/KR102647879B1/ko active Active
- 2016-03-31 MA MA041863A patent/MA41863A/fr unknown
- 2016-03-31 AU AU2016243700A patent/AU2016243700B2/en active Active
- 2016-03-31 LT LTEPPCT/US2016/025235T patent/LT3277270T/lt unknown
- 2016-03-31 MY MYPI2017703613A patent/MY192705A/en unknown
- 2016-03-31 SG SG11201707994UA patent/SG11201707994UA/en unknown
- 2016-03-31 SI SI201631401T patent/SI3277270T1/sl unknown
- 2016-03-31 PE PE2017001640A patent/PE20180189A1/es unknown
- 2016-03-31 HR HRP20211862TT patent/HRP20211862T1/hr unknown
- 2016-03-31 CR CR20210248A patent/CR20210248A/es unknown
- 2016-03-31 US US15/563,169 patent/US11324734B2/en active Active
- 2016-03-31 TW TW112103174A patent/TWI836883B/zh active
- 2016-03-31 UA UAA201710516A patent/UA123308C2/uk unknown
- 2016-03-31 PL PL16774184T patent/PL3277270T3/pl unknown
- 2016-03-31 EA EA201792182A patent/EA036920B1/ru unknown
- 2016-03-31 IL IL292262A patent/IL292262B2/en unknown
- 2016-03-31 EP EP16774184.2A patent/EP3277270B1/en active Active
- 2016-03-31 IL IL305910A patent/IL305910B2/en unknown
- 2016-03-31 NZ NZ735973A patent/NZ735973A/en unknown
- 2016-03-31 TW TW113105456A patent/TWI881714B/zh active
- 2016-03-31 TW TW110101093A patent/TWI794725B/zh active
- 2016-03-31 JP JP2017551039A patent/JP6929785B2/ja active Active
- 2016-03-31 EP EP21199787.9A patent/EP3995138A1/en active Pending
- 2016-03-31 TW TW105110394A patent/TWI718138B/zh active
- 2016-03-31 WO PCT/US2016/025235 patent/WO2016161094A1/en not_active Ceased
- 2016-03-31 CN CN202211214971.7A patent/CN115607521A/zh active Pending
- 2016-03-31 BR BR112017021097-5A patent/BR112017021097B1/pt active IP Right Grant
- 2016-03-31 DK DK16774184.2T patent/DK3277270T3/da active
- 2016-03-31 KR KR1020247008210A patent/KR102866021B1/ko active Active
- 2016-03-31 PT PT167741842T patent/PT3277270T/pt unknown
- 2016-03-31 MX MX2017012460A patent/MX374909B/es active IP Right Grant
- 2016-03-31 ES ES16774184T patent/ES2900481T3/es active Active
- 2016-03-31 CN CN201680030930.9A patent/CN107645953B/zh active Active
- 2016-03-31 KR KR1020257032098A patent/KR20250150155A/ko active Pending
- 2016-03-31 HU HUE16774184A patent/HUE056958T2/hu unknown
-
2017
- 2017-09-26 IL IL254710A patent/IL254710B/en unknown
- 2017-09-28 SA SA517390054A patent/SA517390054B1/ar unknown
- 2017-09-28 MX MX2021012155A patent/MX2021012155A/es unknown
- 2017-09-29 CL CL2017002456A patent/CL2017002456A1/es unknown
- 2017-10-04 ZA ZA2017/06681A patent/ZA201706681B/en unknown
- 2017-10-31 CO CONC2017/0011200A patent/CO2017011200A2/es unknown
- 2017-11-01 EC ECIEPI201773209A patent/ECSP17073209A/es unknown
-
2019
- 2019-07-10 CL CL2019001927A patent/CL2019001927A1/es unknown
-
2020
- 2020-10-02 ZA ZA2020/06107A patent/ZA202006107B/en unknown
- 2020-11-18 AU AU2020273282A patent/AU2020273282B2/en active Active
-
2021
- 2021-08-11 JP JP2021131241A patent/JP7270688B2/ja active Active
- 2021-12-13 CY CY20211101090T patent/CY1124869T1/el unknown
-
2022
- 2022-04-04 US US17/712,709 patent/US11844756B2/en active Active
-
2023
- 2023-01-18 AU AU2023200252A patent/AU2023200252B2/en active Active
- 2023-04-25 JP JP2023071337A patent/JP7629049B2/ja active Active
- 2023-11-02 US US18/500,471 patent/US20240325361A1/en active Pending
-
2025
- 2025-01-30 JP JP2025013506A patent/JP2025069280A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3277270T3 (pl) | Kompozycje i sposoby leczenia niedokrwistości | |
| IL282048A (en) | Oxysterols and methods of use thereof | |
| ZA201801511B (en) | Flavonoid compositions and methods of use | |
| EP4212536C0 (en) | BENZOXAZEPINE OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | |
| PT3142637T (pt) | Formulações e métodos de tratamento de queratina | |
| DK3234133T3 (da) | Crispr-baserede sammensætninger og fremgangsmåder til anvendelse | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| PL3402888T3 (pl) | Środki i sposoby leczenia hbv | |
| EP3313404C0 (en) | THERAPEUTIC COMPOSITIONS, COMBINATIONS AND METHODS OF USE | |
| KR20180084891A (ko) | 구조 조성물 및 방법 | |
| DK3557998T3 (da) | Sammensætninger, kompositioner og anvendelsesmetoder | |
| HUE056287T2 (hu) | Pancreatitis kezelése | |
| PL3200815T3 (pl) | Sposoby i kompozycje do leczenia nowotworu | |
| IL257784A (en) | Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition | |
| PL3189074T3 (pl) | Kompozycje oraz sposoby leczenia i zapobiegania zapaleniom | |
| PL3394259T3 (pl) | Kompozycje i sposoby zmniejszania ekspresji tau | |
| DK3194564T3 (da) | Trichodermasammensætninger og anvendelsesfremgangsmåder | |
| IL256322B (en) | Improved formulations of deferasirox and methods of making the same | |
| DK3209696T3 (da) | Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom | |
| PL3389636T3 (pl) | Kompozycje i metody wytwarzania mikrocząstek białkowych | |
| EP3310376A4 (en) | MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF | |
| DK3261644T3 (da) | Sammensætninger og fremgangsmåder til behandling af nethindenedbrydning | |
| DK3142664T3 (da) | Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme | |
| DK3288379T3 (da) | Peptidsammensætninger og anvendelsesmåder | |
| PL3393468T3 (pl) | Metody leczenia niedoboru odporności |